Adaptation to Robust Monolayer Expansion Produces Human Pluripotent Stem Cells With Improved Viability. (13th March 2013)

• Record Type: Journal Article
• Authors: Kunova, Michaela; Matulka, Kamil; Eiselleova, Livia; Salykin, Anton; Kubikova, Iva; Kyrylenko, Sergiy; Hampl, Ales; Dvorak, Petr
• Is Part Of: Stem cells translational medicine. Volume 2:Number 4(2013)
• Page Start: 246
• Page End: 254
• Publication Date: 2013-03-13
• Subjects: Embryonic stem cells -- Cell culture -- Xenograft assay -- Cell survival -- Induced pluripotent stem cells; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.5966/sctm.2012-0081
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract : This study presents an efficient feeder‐free, high‐density monolayer system in which human pluripotent stem cells (hPSCs) become SSEA‐3‐high and gradually more viable than their feeder‐dependent counterparts without changes attributed to culture adaptation. This monolayer culture system is highly suitable for long‐term, large‐scale propagation of hPSCs, which is necessary in drug development and pluripotent stem cell‐based therapies. Abstract : The generation of human pluripotent stem cells (hPSCs) of sufficient quantity and quality remains a major challenge for biomedical application. Here we present an efficient feeder‐free, high‐density monolayer system in which hPSCs become SSEA‐3‐high and gradually more viable than their feeder‐dependent counterparts without changes attributed to culture adaptation. As a consequence, monolayer hPSCs possess advantages over their counterparts in embryoid body development, teratoma formation, freezing as a single‐cell suspension, and colony‐forming efficiency. Importantly, this monolayer culture system is reversible, preserving the competence of hPSCs to gradually reacquire features of colony growth, if necessary. Therefore, the monolayer culture system is highly suitable for long‐term, large‐scale propagation of hPSCs, which is necessary in drug development and pluripotent stem cell‐based therapies.